Lenalidomida Generis (Lenalidomide)

• Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.
• Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
• Mantle Cell Lymphoma: contributes to disease control in patients receiving combination therapy.

• Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This interaction promotes ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to reduced proliferation of malignant cells, enhanced immune‑mediated tumor cell killing, inhibition of angiogenesis, and modulation of cytokine production. It also affects the tumor microenvironment by decreasing stromal support and altering adhesion molecule expression.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Neutropenia: decreased neutrophil count leading to infection risk.
• Thrombocytopenia: reduced platelet levels causing easy bruising.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of sickness often accompanied by vomiting.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: profound drop in neutrophils with febrile episodes.
• Secondary primary malignancies: emergence of new cancers unrelated to original disease.

• When prescribing Lenalidomida Generis, clinicians should observe several safety measures.
• Monitor blood counts: perform regular CBC to detect neutropenia or thrombocytopenia.
• Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients.
• Contraindicated in pregnancy: avoid use due to potential teratogenicity; ensure effective contraception.
• Infection vigilance: monitor for signs of infection and manage promptly.
• Drug interaction awareness: review concomitant medications that affect CYP3A4 or increase clot risk.
• Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Lenalidomida Generis can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure.
• Anticoagulants combined with high thrombotic risk: may exacerbate clot formation.
• Teratogenic agents used concurrently: additive risk of birth defects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• P‑gp inhibitors (e.g., amiodarone): could modestly raise plasma levels.
• Live vaccines: immunomodulation may diminish vaccine effectiveness.